SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Life Sciences gets USFDA nod for Donepezil Hydrochloride

06 Jun 2011 Evaluate

Jubilant Life Sciences has received approval from the US Food and Drug Administration (USFDA) for Donepezil Hydrochloride Tablets 5 mg and 10 mg, a generic equivalent of Aricept.

Donepezil Hydrochloride tablets are indicated for the treatment of dementia of the Alzheimer’s type, in patients with mild, moderate and severe Alzheimer’s disease. The total annual market sales for Aricept 5 mg and 10 mg tablets were $2.6 billion.

Donepezil Hydrochloride Tablets will be manufactured at the company’s state of the art dosage form facility at Roorkee in India, with backward integration into the API manufactured at the company’s USFDA approved API facility at Nanjangud in India. The product will be marketed by its US subsidiary Jubilant Cadista Pharmaceuticals Inc. under its label. With this approval Jubilant Cadista will have 15 commercialized products in the US market.

The company along with its subsidiary Cadista currently holds 17 ANDA approvals and has a pipeline of 19 ANDAs awaiting approvals from the US FDA.

Jubilant Life Sciences is an integrated Pharma and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution (DDDS) provider out of India.

Jubilant Pharmova Share Price

973.45 3.70 (0.38%)
05-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.55
Dr. Reddys Lab 1277.80
Cipla 1400.70
Zydus Lifesciences 1088.90
Lupin 2268.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×